Here was the first:
And here was the second (already cited):Quote:00:17:17:08 - 00:17:53:17
So just a summary. We saw a 98% reduction of metastases, as I mentioned. I mentioned the retrospective clinical data that I outlined, and the clinical outcomes. But I think importantly, the next steps we're going to submit to the FDA, follow up phase two proof of concept protocol for PD-L1 negative TNBC patients. These patients currently ineligible for ICI therapy will receive Leronlimab plus standard chemotherapy for two cycles, followed by a regimen of Leronlimab with an ICI.
00:17:53:20 - 00:18:17:14
And then, interestingly enough, we actually plan on opening an expanded access protocol submission to the FDA. I think that will give us a lot of real world data in that regard. One really interesting thing that I want to tell everyone here is that we do have a commitment from an outside source to fund this expanded access program.
00:18:17:14 - 00:18:38:06
It's a very high net worth individual who wants to not only pay for this, fund this, but also a glioblstoma investigator initiated trial. So really excited, to kind of team up with this individual.
Quote:00:40:09:12
We're looking for, we do have a very very very very high net worth individual who has agreed in principle to fund our expanded access program. So we're looking forward to closing that in the very near future, and that'll be a nice, a nice outcome. Those will be in triple negative breast cancer patients who are otherwise ineligible or unable to, be in our, planned phase two clinical trial.
There are ways for a person to fund a trial and keep his name off the clinicaltrials.gov site. But even so, it was Hoffman's slip-ups, and I'm sure he apologizes.